Palbociclib/Palbociclib drug introduction

Palbociclib/Palbociclib is an oral anti-cancer drug mainly used to treat certain types of breast cancer. As an inhibitor of cyclin-dependent kinase (CDK) 4/6, it hinders the proliferation and spread of tumor cells by acting on these key enzymes, providing a new treatment option for breast cancer patients.

When using palbociclib, patients need to follow a specific drug cycle: take it orally every day with food, every a treatment cycle of 21 days, followed by a 7-day break. Currently, the drug is often combined with drugs such as letrozole or fulvestrant to further enhance the effectiveness of the treatment. Also, patients should avoid taking CYP3A inhibitors or inducers, as well as grapefruit products, as these may affect drug metabolism and absorption.

In the field of breast cancer treatment, palbociclib is particularly suitable for patients with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This drug, used in combination with an aromatase inhibitor (such as letrozole or fulvestrant), has become the endocrine therapy of choice for postmenopausal women.

Clinical studies have shown that the combination of palbociclib and an aromatase inhibitor can significantly extend the progression-free survival (PFS) of patients with advanced breast cancer and may improve the overall survival rate. This is due to palbociclib's inhibition of CDK4/6 activity, which can interfere with cell cycle progression and slow down tumor growth.

However, patients also need to be aware of possible side effects when using palbociclib. Some common adverse reactions include leukopenia, fatigue, nausea, diarrhea and infection. Fortunately, these side effects can usually be managed and alleviated with dosage adjustments or symptomatic treatment directed by your doctor.

In summary, palbociclib/palbociclib, as a highly efficient anti-cancer drug, has shown significant efficacy in the treatment of HR-positive, HER2-negative advanced breast cancer. Patients should strictly follow their doctor's advice when using it and monitor possible side effects.